Literature DB >> 29848701

Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro Study.

Luca Triggiani1, Antonella Colosini1, Michela Buglione2, Nadia Pasinetti1, Flavia Orizio3, Lilia Bardoscia1, Paolo Borghetti1, Marta Maddalo1, Luigi Spiazzi4, Stefano Maria Magrini1, Roberto Bresciani3.   

Abstract

BACKGROUND/AIM: Androgen receptor plays a key role in prostate cancer development and is a causative agent of its radio-resistance. The present study investigated the potential radio-sensitizing effect of enzalutamide, a second-generation anti-androgen, in human prostate cancer cells.
MATERIALS AND METHODS: The radio-sensitizing effect of enzalutamide was assessed in the androgen-dependent LNCaP cells and the androgen-independent PC3 cells by clonogenic assay and γ-H2AX assay.
RESULTS: Enzalutamide-treated LNCaP cells showed a significant decrease of cell survival at all radiation doses tested. An increased number of γ-H2AX-positive nuclei was observed, suggesting a possible impairment of the DNA repair machinery. Conversely, enzalutamide did not exhibit a significant radio-sensitizing effect on PC3 cells.
CONCLUSION: The combination of enzalutamide with ionizing radiation significantly improves radio-sensitivity of hormone-dependent LNCaP cells. Translated in the clinical practice, our results may help to find additional strategies to improve effectiveness of radiotherapy. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; androgen receptor; enzalutamide; ionizing radiation; γ-H2AX

Mesh:

Substances:

Year:  2018        PMID: 29848701     DOI: 10.21873/anticanres.12619

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Apalutamide radio-sensitisation of prostate cancer.

Authors:  Christos Kakouratos; Dimitra Kalamida; Ioannis Lamprou; Erasmia Xanthopoulou; Christos Nanos; Alexandra Giatromanolaki; Michael I Koukourakis
Journal:  Br J Cancer       Date:  2021-09-01       Impact factor: 9.075

2.  The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.

Authors:  Jin Xu; Xi Yang; Dhanraj Deshmukh; Hegang Chen; Shengyun Fang; Yun Qiu
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.